ERCC1、RRM1基因表达与非小细胞肺癌患者预后的相关性

目的探讨ERCC1、RRM1基因蛋门表达对Ⅰ～Ⅲa期非小细胞肺癌患者预后的影响。方法采用免疫组化法检测Ⅰ～Ⅲa期非小细胞肺癌患者ERCC1、RRM1蛋白表达情况；采用生存分析曲线分析其对生俘预后的影响。结果ERCCl、RRMl蛋白表达与患者性别、年龄、病珲类型和TNM分期等莘异均无统计学意义（P〉0．05）。在TNM分期中，Ⅰa期ERCCl、RRM1阳性表达组生存预后较好，提示两种基因蛋白的阳性表达在18期患者中是一种保护因素。存IhⅢa期患者中ERCC1表达阴性组可以从含铂化疗方案中获益，可获得生存优势；RRMI表达阴性组对化疗药物吉西他滨敏感，可获得较长的生存优势。在Ⅰ～Ⅲa期患者中ERCC1与RRM1的表达呈正相关，差异有统计学意义（P〈0．05）。结论检测Ⅰ～Ⅲa期非小细胞肺癌ERCCI及RRM1蛋白表达可以预测患者的治疗疗效及预后，使患者从个体化治疗中获益。

Correlation of ERCC1 and RRM1 expression and survival prognosis in non-small cell lung cancer patients

Objective To explore the effects of excision repair cross-complementing I（ERCCI ） and ribonucleotide reductase subunit （RRM1） protein expression on survival Drognosis of stage Ⅰ-Ⅲa non-small cell lung cancer（NSCLC） patients. Methods ERCC1 and RRM1 protein expression was detected in stage Ⅰ-Ⅲa NSCLC patients using irnmunohistochemistry.The survival prognosis of the patients was analyzed by survival analysis. Results Neither ERCC1 nor RRMI expression was associated with gender,age,histological type,or TNM stage.The survival prognosis of ERCCI-and RRMl-positive patients in stage la was better than that of ERCCI-and RRMl-positive patients in other stages.ERCCl-negative patients in stage Ⅰ-Ⅲa may benefit from platinum-containing chemotherapy,which may provide a survival advantage.RRMl-negative patients were sensitive to gemcitabine, which provided a survival advantage. ERCC 1 expression positively correlated with RRM1 expression（P〈0.05） in stage I-IIIa NSCLC patients. Conclusion Chemotherapeutic effect and prognosis of patients with stage I-IIIa NSCLC can be predicted by detecting ERCC1 and RRM1 expression,which may allow for individualized treatment plans.